Inclisiran in Chronic Kidney Disease Patients: A Real-World Experience
Cardiorenal Medicine · 04.02.2026 · 16 (1) · 87-94
DOI: 10.1159/000549898 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cardiorenal Medicine, online erschienen am 04.02.2026. Verfasst von Andrea Dello Strologo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Dialysis, Azienda USL Roma 6, Albano Laziale, Italy. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Hypercholesterolemia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Patients with chronic kidney disease (CKD) have a high incidence of morbidity and mortality from cardiovascular causes. Among the most significant cardiovascular risk factors is undoubtedly hypercholesterolemia, especially elevated cholesterol LDL levels. The first-line therapy for the management of hypercholesterolemia, including in patients with CKD, is represented by statins even in combination with ezetimibe. In patients with CKD, statin therapy is often poorly tolerated with high incidence of rhabdomyolysis. An alternative treatment is represented by small interfering RNA inclisiran, which has been shown to be effective in double yearly administration.
Methods
Thirty-two patients (19 males and 13 females) with a mean age of 60.2 years, basal total cholesterol values of 225 mg/dL and LDL cholesterol values of 138 mg/dL were enrolled in our observational study. The mean eGFR value at baseline was 36.93 mL/min/m2. All patients had a diagnosis of chronic ischemic heart disease (CAD), and 4 patients also had type 2 diabetes mellitus. The patients received therapy with inclisiran 284 mg at time zero, then repeated at 3 months and then at 6 months.
Results
After 12 months of treatment, there was almost 50% reduction in both total and LDL cholesterol values with no significant change in eGFR values. Only one patient presented with an episode of myocardial infarction 11 months after treatment was started, and no drug-related side effects were reported.
Conclusion
Inclisiran should be considered as a viable therapeutic alternative for the management of pure hypercholesterolemia in patients with CKD who are intolerant to statin treatment because it achieves the optimal LDL cholesterol targets required by actual guidelines without side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology and Dialysis, Azienda USL Roma 6, Albano Laziale, Italy.
- Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
- Service of Nephrology, Ospedale Regionale Di Lugano, Ospdeale Civico, Ente Ospedaliero Cantonale, Lugano, Switzerland, antonio.bellasi@usi.ch.
- Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome, Italy.
- International Renal Research Institute and IRRIV Foundation for Research in Nephrology, Dialysis and Transplantation, San Bortolo Hospital, Vicenza, Italy.
Zitieren
APA
Dello Strologo, A., Franculli, A., Saporito, P., Miani, N., Bellasi, A., Lido, P., Di Lullo, L., Ronco, C., & Peverini, P. (2026). Inclisiran in Chronic Kidney Disease Patients: A Real-World Experience. Cardiorenal Medicine, 16(1), 87-94. https://doi.org/10.1159/000549898
Vancouver
Dello Strologo A, Franculli A, Saporito P, Miani N, Bellasi A, Lido P, et al. Inclisiran in Chronic Kidney Disease Patients: A Real-World Experience. Cardiorenal Medicine. 2026;16(1):87-94. doi:10.1159/000549898
BibTeX
@article{DelloStrologo2026,
author = {Dello Strologo, Andrea and Franculli, Aldo and Saporito, Pasquale and Miani, Natascia and Bellasi, Antonio and Lido, Paolo and Di Lullo, Luca and Ronco, Claudio and Peverini, Paola},
title = {Inclisiran in Chronic Kidney Disease Patients: A Real-World Experience},
journal = {Cardiorenal Medicine},
year = {2026},
volume = {16},
number = {1},
pages = {87--94},
doi = {10.1159/000549898}
}
EUVIMED